YOLFTbeta
41

GeneReach Biotechnology

4171 · TWO · Healthcare / Biotechnology

15.20TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close15.20
Open15.05
Day Range15.00 – 15.25
52-Week Range16.05 – 26.90
Volume131.60K
Market Cap929.62M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.74
Dividend Yield0.00%
Beta0.38
50-Day Avg16.87
200-Day Avg18.46

About

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ2000 Detection & Prevention System. It also provides training program; and other services comprising molecular diagnostic technical solutions and laboratory installation, OEM/ODM contract manufacturing, and research collaborations services. The company was founded in 2004 and is headquartered in Taichung, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. De Yu Zhong
  • Employees0
  • HeadquartersCentral Science Park, Taichung, Taiwan, 407, Taiwan
  • Websitehttps://www.genereach.com

Leadership

  • Mr. Zhengzhong Liu MScChairman of the Board & Head of Public Relations
  • Mr. De Yu ZhongCEO & Director
  • Mr. Lu Yuan LiuChief Operating Officer
  • Ms. Shuyu CaoAccounting Supervisor
  • Ms. Yu-Wen HuangVice President of Compliance & Production Department
  • Ms. Xiu Ying ZhangTreasurer

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue155.41M187.42M365.80M857.03M1.01B750.02M225.46M206.49M232.74M
Growth (%)-+20.60%+95.18%+134.29%+18.09%-25.89%-69.94%-8.41%+12.71%
Cost of Revenue30.00M38.06M63.75M221.59M265.10M259.95M197.88M88.21M71.81M
Gross Profit125.41M149.36M302.04M635.45M746.98M490.07M27.58M118.28M160.93M
Gross Margin80.70%79.69%82.57%74.14%73.81%65.34%12.23%57.28%69.14%
Operating Expense146.83M136.59M188.10M290.69M266.29M212.22M218.74M254.14M247.84M
Operating Income-21.42M12.76M113.94M344.75M480.69M277.85M-191.15M-135.86M-86.92M
Operating Margin-13.78%6.81%31.15%40.23%47.50%37.05%-84.78%-65.80%-37.34%
EBITDA-23.89M49.63M135.56M396.59M540.70M343.02M-122.26M-36.31M-38.86M
EBITDA Margin-15.37%26.48%37.06%46.27%53.42%45.73%-54.23%-17.58%-16.70%
Net Income-48.13M28.57M77.18M257.28M376.62M221.34M-166.27M-118.73M-110.28M
Net Income Margin-30.97%15.24%21.10%30.02%37.21%29.51%-73.75%-57.50%-47.38%
R&D33.48M29.46M40.95M68.78M56.61M58.81M61.46M80.51M72.75M
R&D as % of Total Revenue21.54%15.72%11.20%8.03%5.59%7.84%27.26%38.99%31.26%
Interest Expense06.63M4.14M3.82M6.26M6.61M5.76M5.93M6.51M
Interest Expense % of Total Revenue0.00%3.54%1.13%0.45%0.62%0.88%2.56%2.87%2.80%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets602.84M693.83M760.87M1.24B1.68B1.62B1.18B1.07B881.05M
Total Liabilities352.21M382.68M167.82M382.75M596.35M519.23M313.71M341.00M284.34M
Total Equity250.63M288.85M555.54M813.01M1.05B1.07B832.06M716.98M586.73M
Cash114.87M99.52M177.02M313.68M663.43M748.61M216.77M110.27M155.07M
Total Debt---207.30M394.61M402.50M257.04M--
Net Debt195.12M227.25M--106.38M-268.83M-346.12M40.27M66.51M-

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.83M5.74M-11.19M169.82M348.99M357.63M-38.67M-23.22M-13.52M
Investing Cash Flow-100.39M-31.42M220.53M-108.90M-41.70M----
Financing Cash Flow92.00M14.84M-129.79M75.05M43.48M-228.28M-215.88M--
Capital Expenditure895.00K2.31M13.53M64.87M15.79M44.90M27.36M8.47M11.64M
Free Cash Flow-8.43M3.44M-24.93M104.95M333.20M312.73M-66.03M-31.69M-25.15M
Dividends Paid-143.67M143.67M143.67M143.67M208.94M68.95M15.99M-
FCF to OCF123.51%59.82%222.76%61.80%95.48%87.44%170.73%136.46%186.11%
Dividend Paid to FCF-4181.32%-576.22%136.90%43.12%66.81%-104.42%-50.46%-

Earnings

Report DateMay 28, 2014Sep 3, 2014Dec 3, 2014Feb 25, 2015May 11, 2015Aug 13, 2015Nov 10, 2015Mar 25, 2016May 10, 2016Aug 5, 2016Nov 14, 2016Mar 24, 2017May 15, 2017Aug 11, 2017Nov 9, 2017Mar 22, 2018May 11, 2018Aug 13, 2018Nov 13, 2018Mar 26, 2019May 14, 2019Aug 12, 2019Nov 13, 2019Mar 30, 2020May 16, 2020Aug 14, 2020Nov 11, 2020Mar 18, 2021May 12, 2021Aug 6, 2021Nov 12, 2021Mar 11, 2022May 6, 2022Aug 9, 2022Nov 10, 2022Mar 23, 2023May 9, 2023
EPS Estimate-------------0.07-0.08-0.07-0.23-0.10-0.080.140.130.390.370.35-2.907.28----------
EPS Actual-0.31-0.15-0.07-0.14-0.36-0.180.15-0.26-0.17-0.05-0.24-0.53-0.320.06-0.12-0.610.180.440.040.060.570.420.320.260.322.001.471.971.992.382.331.342.092.890.80-1.14-0.81
Surprise-------------357.14%175.00%-71.43%-165.22%280.00%--50.00%-57.14%338.46%7.69%-13.51%-25.71%--31.03%-79.81%----------
Timing----Pre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap929.62M
Enterprise Value754.06M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.90
Price / Book1.62
EPS-0.74
Book Value10.07
Revenue (TTM)238.08M
Gross Profit (TTM)173.30M
EBITDA-6.46M
Profit Margin-18.10%
Operating Margin-14.08%
Return on Equity-7.60%
Return on Assets-3.70%
Shares Outstanding56.86M
Shares Float38.69M
Beta0.38
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
1.50Jul 28, 2023
20221×
4.00Sep 13, 2022
20211×
2.57Oct 7, 2021

Stock Splits

  • Jul 28, 20231250:1000
  • Sep 13, 20221100:1000
  • Oct 7, 20211029.496:1000